Abstract

目的探讨慢性中性粒细胞白血病(CNL)患者的临床表现、细胞遗传学和基因突变等实验室特征及预后因素。方法对符合2016年WHO诊断分型标准的16例CNL患者进行资料采集,随访患者并进行预后分析。利用直接测序法检测CSF3R、ASXL1、SETBP1、CALR、MPL基因突变状态,对有突变的样本进行克隆后测序鉴定,采用等位基因特异性聚合酶链反应(AS-PCR)检测JAK2 V617F突变。结果16例CNL患者中位发病年龄为64(43~80)岁,男性占75%(12/16),确诊时中位HGB水平为114(81~154)g/L,中位WBC为41.20(26.05~167.70)×109/L,中位PLT为238(91~394)×109/L。中位骨髓纤维化水平为1(0~3)级。除1例t(1;7)(p32;q11)、1例+21克隆异常及1例14ps+外,余患者均为正常核型。16例CNL患者中,CSF3R T618I突变检出率为100%(16/16),ASXL1突变检出率为81%(13/16),SETBP1突变检出率为63%(10/16),1例患者携带CALR K385fs*47突变,所有患者均无JAK2 V617F突变及MPL突变。CNL患者中位生存期为24(95%CI 18~30)个月。初诊WBC≥50×109/L者中位生存期较<50×109/L者短(11个月对39个月,P=0.005)。结论CSF3R T618I突变是CNL的特异性突变。CNL患者中位生存期24个月,确诊时WBC≥50×109/L是不良预后因素。

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.